Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 4—April 2020
Synopsis

Decreased Susceptibility to Azithromycin in Clinical Shigella Isolates Associated with HIV and Sexually Transmitted Bacterial Diseases, Minnesota, USA, 2012–2015

Dana EikmeierComments to Author , Pamela Talley, Anna Bowen, Fe Leano, Ginette Dobbins, Selina Jawahir, Annastasia Gross, Dawn Huspeni, Allison La Pointe, Stephanie Meyer, and Kirk Smith
Author affiliations: Minnesota Department of Health, St. Paul, Minnesota, USA (D. Eikmeier, F. Leano, G. Dobbins, S. Jawahir, A. Gross, D. Huspeni, A. La Pointe, S. Meyer, K. Smith); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (P. Talley, A. Bowen)

Main Article

Figure 1

Number of Shigella isolates for which AST was conducted, by demographic group among isolates received at the Minnesota Department of Health, 2012–2015. AST, antimicrobial susceptibility testing.

Figure 1. Number of Shigella isolates for which AST was conducted, by demographic group among isolates received at the Minnesota Department of Health, 2012–2015. AST, antimicrobial susceptibility testing.

Main Article

Page created: March 17, 2020
Page updated: March 17, 2020
Page reviewed: March 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external